Clinical and Economic Burden of Illness in Patients with Persistent or Chronic Primary Immune Thrombocytopenia Treated with TPO-Ras and Rituximab
David J. Kuter(Harvard University), Natalia Petruski‐Ivleva(AVEO Oncology (United States)), Ines Hemim(Sanofi (United States)), Imène Gouia(Sanofi (France)), Siddhi Umarje, Matias Cordoba, Brad Ward(Sanofi (United States))
Cited by 2
Related Papers
Updated international consensus report on the investigation and management of primary immune thrombocytopenia
|Blood Advances|2019|1.1k
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP
|New England Journal of Medicine|2006|530
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
|New England Journal of Medicine|2010|425
Dietary Protein Sources and Risk for Incident Chronic Kidney Disease: Results From the Atherosclerosis Risk in Communities (ARIC) Study
|Journal of Renal Nutrition|2017|254